Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavituximab - Avid Bioservices

Next Previous
X
Search
Drug Profile

Bavituximab - Avid Bioservices

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avid Bioservices; University of Texas M. D. Anderson Cancer Center
  • Developer Avid Bioservices; Feng Biosciences; IMV; Massachusetts General Hospital; Merck Sharp & Dohme; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
  • Suspended Breast cancer; HER2 negative breast cancer; Malignant melanoma; Pancreatic cancer
  • No development reported Brain cancer; Hepatitis C; HIV infections; Rectal cancer; Solid tumours; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 22 Aug 2023 Massachusetts General Hospital Cancer Center completes a phase II trial for Glioblastoma (Combination therapy; Newly diagnosed disease) in USA (IV) (NCT03139916)
  • 02 Jun 2023 Adverse events and efficacy data from a phase II trial in Gastric cancer and Oesophageal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 20 Jan 2023 Final efficacy and safety data from a phase II trial in liver cancer presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top